Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542558 | 0.85 | HSD11B1 (0.66) | HSD11B1SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL17761202 | 0.83 | DPP4 (0.56) | HSD11B1SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL3545191 | 0.83 | HSD11B1 (0.63) | HSD11B1DPP4LMNAHSD17B10L3MBTL1 | |
| SCHEMBL4866308 | 0.81 | DPP4 (0.58) | HSD11B1SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL6491320 | 0.80 | HSD11B1 (0.51) | HSD11B1SLC6A3SLC6A4SLC6A2LMNA | |
| SCHEMBL17761297 | 0.80 | HSD11B1 (0.73) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12836593 | 0.80 | SLC6A3 (0.62) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17761201 | 0.80 | HSD11B1 (0.51) | HSD11B1SLC6A3SLC6A4SLC6A2L3MBTL1 | |
| SCHEMBL3548281 | 0.80 | HSD11B1 (0.44) | HSD11B1SLC6A3SLC6A4SLC6A2LMNA | |
| SCHEMBL3543773 | 0.80 | HSD11B1 (0.44) | HSD11B1SLC6A3SLC6A4SLC6A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | HSD11B1 117/4885SLC6A3 413/4885SLC6A4 886/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | HSD11B1 126/4885SLC6A3 363/4885SLC6A4 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.